Illumina, Inc. (NASDAQ: ILMN) announced today that the High Court of
Justice, Chancery Division, Patents Court in the United Kingdom issued a
judgment in its favor in the patent infringement suit filed against
Ariosa Diagnostics, Inc.
The Court found that Ariosa’s Harmony non-invasive prenatal test
infringed EP 1 524 321 and that the patent claims were valid. The patent
is directed to the size selection of extracellular DNA in maternal
plasma samples. Size selection boosts the fetal fraction, leading to
fewer test samples being rejected for low fetal fraction.
“We are pleased that the UK Court has again ruled in our favor,
continuing to affirm the value of our NIPT portfolio and the significant
contributions of the inventors in this field,” said Charles Dadswell,
Senior Vice President and General Counsel at Illumina.
Illumina intends to seek all available remedies for the infringement,
including damages, injunctive relief, and attorney fees.
About Illumina
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
follow @illumina.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190617005842/en/